A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).

Akihiko Shimomura,Kenji Tamura,Tomonori Mizutani,Taro Shibata,Fumikata Hara,Tomomi Fujisawa,Naoki Niikura,Takashi Hojo,Chizuko Kanbayashi,Shigehira Saji,Norikazu Masuda,Masataka Sawaki,Naohito Yamamoto,Fumio Nagashima,Tadahiko Shien,Hiroji Iwata

A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).

2019

Akihiko Shimomura
Kenji Tamura
Tomonori Mizutani
Taro Shibata
Fumikata Hara
Tomomi Fujisawa
Naoki Niikura
Takashi Hojo
Chizuko Kanbayashi
Shigehira Saji
Norikazu Masuda
Masataka Sawaki
Naohito Yamamoto
Fumio Nagashima
Tadahiko Shien
Hiroji Iwata

TPS1100Background: Systemic chemotherapy with anti-HER2 therapy is the standard of care for HER2-positive advanced breast cancer. Patient outcomes have improved remarkably with the use of novel ant...

Keywords:

HER2 Positive Breast Cancer
Oncology
Internal medicine
Trastuzumab
Medicine
advanced stage
Docetaxel
Cancer
advanced breast
Pertuzumab
Trastuzumab emtansine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations